贝那利珠单抗治疗嗜酸性肉芽肿性多血管炎
这项多中心回顾性研究纳入68例接受超说明书贝那利珠单抗治疗的EGPA患者,33例(49%)达完全缓解、24例(36%)达部分缓解;既往使用美泊利珠单抗与更高的原发失败率和更少的糖皮质激素停用相关。
要点
- 68例EGPA患者中49%达完全缓解、36%部分缓解、15%无应答,38%停用糖皮质激素。
- 既往美泊利珠单抗使用者原发失败率26.7% vs 5.4%(p=0.034),糖皮质激素停用率14.8% vs 55.9%(p=0.001)。
- 血管炎 flare 发生于7例(11%),与贝那利珠单抗起始时组织学血管炎证据和/或ANCA阳性相关(p=0.004)。
核心结论
- 贝那利珠单抗似乎对EGPA难治性哮喘或耳鼻喉表现有效,并允许减少糖皮质激素用量;但既往美泊利珠单抗治疗失败后其疗效较低。
研究设计与样本
- 多中心回顾性研究,纳入68例接受超说明书贝那利珠单抗治疗的EGPA患者,其中31例(46%)既往接受过美泊利珠单抗。
主要发现
- 33例(49%)达完全缓解,24例(36%)达部分缓解,10例(15%)无应答。
- 在初始应答的57例患者中,10例(18%)最终需要进一步治疗。
- 23例(38%)停用糖皮质激素。
- 既往美泊利珠单抗使用与更高的原发失败率相关(26.7% vs 5.4%,p=0.034),且糖皮质激素停用较少(14.8% vs 55.9%,p=0.001)。
- 7例(11%)发生血管炎 flare,与贝那利珠单抗起始时组织学血管炎证据和/或ANCA阳性相关(p=0.004)。
关键数值与推荐
- 完全缓解定义为无疾病活动(伯明翰血管炎活动评分=0)且泼尼松剂量≤4 mg/天。
- 部分缓解定义为无疾病活动且泼尼松剂量≥4 mg/天。
- 贝那利珠单抗使用指征:未控制的哮喘54例(81%)、持续耳鼻喉表现27例(40%)、持续糖皮质激素使用48例(74%)。
- 贝那利珠单抗起始后中位(IQR)随访23(9-34)个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are limited to case reports and small case series. METHODS: We conducted a multicentre, retrospective study including EGPA patients treated with off-label benralizumab. The primary endpoint was the rate of complete response defined as no disease activity (Birmingham Vasculitis Activity Score=0) and a prednisone dose ≤4 mg/day. Partial response was defined as no disease activity and a prednisone dose ≥4 mg/day. RESULTS: Sixty-eight patients were included, including 31 (46%) who had previously received mepolizumab. The use of benralizumab was warranted by uncontrolled asthma in 54 (81%), persistent ear, nose and throat (ENT) manifestations in 27 (40%) and persistent glucocorticoids (GCs) use in 48 (74%) patients. Median (IQR) follow-up after starting benralizumab was 23 (9-34) months. Thirty-three patients (49%) achieved a complete response, 24 (36%) achieved a partial response and 10 (15%) did not respond. Among the 57 patients who initially responded, 10 (18%) eventually required further line treatments. GCs were discontinued in 23 patients (38%). Prior mepolizumab use was associated with a higher rate of primary failure (26.7% vs 5.4%, p=0.034) and less frequent GCs discontinuation (14.8% vs 55.9%, p=0.001). Vasculitis flares occurred in 7 patients (11%) and were associated with histological evidence of vasculitis and/or antineutrophil cytoplasmic antibodies positivity at benralizumab initiation (p=0.004). CONCLUSIONS: Benralizumab appears to be an effective treatment for refractory asthma or ENT manifestations in EGPA and allows GC-sparing. However, its efficacy was lower after prior failure of mepolizumab.
引用
- Cottu A, Groh M, Desaintjean C, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023. PMID: 37550002. doi:10.1136/ard-2023-224624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。